ÂÜÀòÂÒÂ×

Doug Carlson brings over 20 years of experience with a multi-disciplinary background in corporate finance, venture capital, M&A, business development, and commercial operations with both large and emerging growth healthcare companies.

Most recently he was the Chief Operating Officer, Chief Financial Officer, and Chief Compliance Officer of Ikena Oncology, Inc. (NASDAQ: IKNA). At Ikena, he raised over $260M in private and public capital, led the company’s Initial Public Offering (IPO) in March 2021, and built a robust infrastructure to hire and integrate over 50 new employees.

Prior to joining Collegium, Mr. Carlson was Senior Director of Business Development at BTG International, Inc. (LSE: BTG) where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG, Mr. Carlson was Senior Director and Head of U.S. Business Development for Lundbeck A/S (LUN: Copenhagen). Mr. Carlson was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., where he played an integral role in the sale of Ovation to Lundbeck in 2009. Prior to Ovation, Mr. Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Mr. Carlson started his career in the healthcare investment banking group of Cowen & Co. He holds a Bachelor of Arts degree from Trinity College in Hartford, Conn.